Evommune (NYSE:EVMN) Insider Sells $379,462.38 in Stock

Evommune, Inc. (NYSE:EVMN) insider Jeegar Pravinkumar Patel sold 16,687 shares of Evommune stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $22.74, for a total transaction of $379,462.38. Following the transaction, the insider directly owned 46,403 shares of the company’s stock, valued at approximately $1,055,204.22. This trade represents a 26.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Evommune Stock Performance

Shares of NYSE EVMN opened at $19.87 on Friday. Evommune, Inc. has a 1 year low of $13.89 and a 1 year high of $33.20. The stock has a market cap of $715.68 million and a PE ratio of -2.09. The company’s 50-day simple moving average is $23.91.

Evommune (NYSE:EVMN) last issued its earnings results on Thursday, May 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.19. On average, research analysts anticipate that Evommune, Inc. will post -2.86 earnings per share for the current year.

Wall Street Analyst Weigh In

EVMN has been the subject of several recent analyst reports. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $48.00 target price on shares of Evommune in a report on Friday, April 10th. Wall Street Zen raised shares of Evommune from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Evommune in a report on Tuesday, May 26th. Clear Str raised shares of Evommune to a “strong-buy” rating in a report on Tuesday, March 17th. Finally, Evercore reaffirmed an “outperform” rating and issued a $55.00 target price on shares of Evommune in a report on Tuesday, February 10th. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $49.25.

Institutional Trading of Evommune

Several large investors have recently added to or reduced their stakes in the business. Strs Ohio bought a new stake in Evommune during the first quarter valued at approximately $41,000. China Universal Asset Management Co. Ltd. bought a new stake in Evommune during the fourth quarter valued at approximately $34,000. The Manufacturers Life Insurance Company boosted its position in shares of Evommune by 25.3% in the first quarter. The Manufacturers Life Insurance Company now owns 12,812 shares of the company’s stock worth $295,000 after purchasing an additional 2,587 shares during the period. XTX Topco Ltd bought a new position in shares of Evommune in the fourth quarter worth approximately $321,000. Finally, Oxford Asset Management LLP bought a new position in shares of Evommune in the fourth quarter worth approximately $335,000.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.